[
  {
    "variant": "LRRK2 Y1699C",
    "protein_change": {
      "ref": "Y",
      "alt": "C",
      "position": 1699
    },
    "functional_evidence": {
      "effect": "Decreased GTPase activity, weakened ROC-COR dimerization, strengthened intra-molecular interaction",
      "controls_used": [
        "LRRK2 R1441C",
        "LRRK2 T1348N"
      ]
    },
    "acmg_assessment": {
      "step1": {
        "question": "Is the disease mechanism defined?",
        "answer": "Yes. LRRK2 mutations disrupt GTPase activity and protein interactions, leading to PD.",
        "judgment": "Yes"
      },
      "step2": {
        "question": "Are the assays relevant to the disease mechanism?",
        "answer": "Yes. GTPase activity, dimerization, and competition assays are directly tied to LRRK2's role in PD.",
        "judgment": "Yes"
      },
      "step3a": {
        "question": "Are variant controls and replicates sufficient?",
        "answer": "No. The paper does not explicitly mention statistical replicates or control groups for Y1699C.",
        "judgment": "No"
      },
      "step3b": {
        "question": "Is the assay accepted/validated?",
        "answer": "Yes. GTPase activity and dimerization assays are standard in LRRK2 research.",
        "judgment": "Yes",
        "strength": "Max PS3_supporting"
      },
      "step4": {
        "step4b": {
          "question": "How many total variant controls are used?",
          "answer": "2 (R1441C and T1348N).",
          "judgment": "Fewer than 10.",
          "strength": "Max PS3_supporting"
        }
      },
      "functional_evidence_strength": "PS3_supporting",
      "functional_evidence_aim": "Pathogenic"
    }
  },
  {
    "variant": "LRRK2 R1441C",
    "protein_change": {
      "ref": "R",
      "alt": "C",
      "position": 1441
    },
    "functional_evidence": {
      "effect": "Decreased GTPase activity (used as a control for Y1699C comparison)",
      "controls_used": [
        "LRRK2 Y1699C",
        "LRRK2 T1348N"
      ]
    },
    "acmg_assessment": {
      "step1": {
        "question": "Is the disease mechanism defined?",
        "answer": "Yes. LRRK2 mutations disrupt GTPase activity and protein interactions, leading to PD.",
        "judgment": "Yes"
      },
      "step2": {
        "question": "Are the assays relevant to the disease mechanism?",
        "answer": "Yes. GTPase activity and dimerization assays are directly tied to LRRK2's role in PD.",
        "judgment": "Yes"
      },
      "step3a": {
        "question": "Are variant controls and replicates sufficient?",
        "answer": "No. The paper does not explicitly mention statistical replicates or control groups for R1441C.",
        "judgment": "No"
      },
      "step3b": {
        "question": "Is the assay accepted/validated?",
        "answer": "Yes. GTPase activity and dimerization assays are standard in LRRK2 research.",
        "judgment": "Yes",
        "strength": "Max PS3_supporting"
      },
      "step4": {
        "step4b": {
          "question": "How many total variant controls are used?",
          "answer": "2 (Y1699C and T1348N).",
          "judgment": "Fewer than 10.",
          "strength": "Max PS3_supporting"
        }
      },
      "functional_evidence_strength": "PS3_supporting",
      "functional_evidence_aim": "Pathogenic"
    }
  },
  {
    "variant": "LRRK2 T1348N",
    "protein_change": {
      "ref": "T",
      "alt": "N",
      "position": 1348
    },
    "functional_evidence": {
      "effect": "Decreased GTPase activity (used as a control for Y1699C comparison)",
      "controls_used": [
        "LRRK2 Y1699C",
        "LRRK2 R1441C"
      ]
    },
    "acmg_assessment": {
      "step1": {
        "question": "Is the disease mechanism defined?",
        "answer": "Yes. LRRK2 mutations disrupt GTPase activity and protein interactions, leading to PD.",
        "judgment": "Yes"
      },
      "step2": {
        "question": "Are the assays relevant to the disease mechanism?",
        "answer": "Yes. GTPase activity and dimerization assays are directly tied to LRRK2's role in PD.",
        "judgment": "Yes"
      },
      "step3a": {
        "question": "Are variant controls and replicates sufficient?",
        "answer": "No. The paper does not explicitly mention statistical replicates or control groups for T1348N.",
        "judgment": "No"
      },
      "step3b": {
        "question": "Is the assay accepted/validated?",
        "answer": "Yes. GTPase activity and dimerization assays are standard in LRRK2 research.",
        "judgment": "Yes",
        "strength": "Max PS3_supporting"
      },
      "step4": {
        "step4b": {
          "question": "How many total variant controls are used?",
          "answer": "2 (Y1699C and R1441C).",
          "judgment": "Fewer than 10.",
          "strength": "Max PS3_supporting"
        }
      },
      "functional_evidence_strength": "PS3_supporting",
      "functional_evidence_aim": "Pathogenic"
    }
  }
]